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Introduction
With the progression of chronic kidney disease, the preva-
lence of anaemia increases1 mainly due to the impaired renal 
production of erythropoietin as well as the negative effects of 
the uraemic milieu on bone marrow function. Up to 10% of 
patients respond insufficiently to recombinant human eryth-
ropoietin (rHuEpo) due to high erythropoietin resistance in 
particular. Several well known factors, including vitamin and 
iron deficiencies, hyperparathyroidism and chronic inflam-
mation contribute to the increased erythropoietin resistance, 
and the list has not been completed.2,3 Managing this resist-
ance is one of paramount importance, because both anaemia 
and high delivered dose of rHuEpo have been associated 
with an increased mortality.4–7
The role of the renin-angiotensin system in erythropoie-
sis was gradually revealed over the past decades.8–10 Early 
in vitro studies proved that AT-II (angiotensin-II) could 
accelerate iron incorporation in erythrocytes accompany-
ing an accelerated erythropoiesis.11 Angiotensin-converting 
enzyme (ACE) may be implicated in the regulation of 
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haematopoietic stem cell proliferation leading to acceler-
ated stem cell mitosis and further differentiation to eryth-
roid progenitors.12,13 Angiotensin–II type 1 receptor (AT1R) 
was found on the surface of erythroid progenitor cells,14 
and the AT-II stimulatory effect on erythropoiesis could be 
reversed by the AT1R-blocker, losartan.15 Angiotensin 
increases erythropoietin production due to renal hypoxia in 
the preclinical model of 1967.16 Later research proved this 
result in healthy human volunteers. What is more, the hae-
mopoietic effect of AT-II could be blocked by AT1R block-
ers,17,18 ACE inhibitor (ACEi) therapy decreased the serum 
AT-II level resulting in decreased serum erythropoietin 
concentration in healthy volunteers which was reversible 
after withdrawal of ACEi drugs.19 Increased AT1R expres-
sion on erythroid progenitor cells was also detected in kid-
ney transplant patients with post-transplant erythrocytosis 
syndrome20 and reducing the AT-II level by ACEi can 
induce apoptosis of erythroid precursors in post-transplant 
erythrocytosis syndrome.21 Consequently, ACEi and also 
AT1R blockers have been become a standard therapy for 
this syndrome.22,23 There are also some common intracel-
lular signals induced by AT-II and erythropoietin.24,25 In 
addition, inhibition of ACE was shown to reduce serum 
level of other erythropoiesis-stimulating factors such as 
insulin-like growth factor-1 and interleukin 12.26,27 
Inhibition of the renin-angiotensin system has been reported 
to slow down the rate of erythropoiesis resulting in anaemia 
in a variety of clinical conditions28–32 or to increase rHuEpo 
requirements in dialysis patients.33,34 However, others could 
not confirm these results in chronic dialysed patients.35,36 
The ACE gene insertion/deletion (I/D) polymorphism 
highly influences the serum concentration of ACE enzyme. 
This polymorphism is one of the factors most responsible 
for a wide interpersonal variability of serum ACE concen-
tration. Individuals with the D allele have significantly 
higher serum ACE concentration than subjects with the I 
allele.37,38 Some studies found that the ACE gene I/D poly-
morphism was associated with erythropoietin resistance39–42 
while others could not prove this relationship.43
In our study, we hypothesised that the ACE gene I/D 
polymorphism has an impact on the effect of ACE inhibi-
tor therapy on erythropoiesis. In a retrospective cohort of 
haemodialysis patients, we examined whether the D/D 
genotype was associated with higher haemoglobin and/or 
with lower erythropoietin requirements and if pharmaco-
logical inhibition of ACE can impair erythropoiesis. 
Furthermore, we examined the combined effect of ACE 
gene I/D polymorphism and ACEi therapy on erythropoie-
sis in haemodialysed patients.
Subjects and methods
Eleven dialysis centres of B. Braun Avitum Hungary CPLC 
participated in this Hungarian cross-sectional multicentre 
observational Angiotensin-converting enzyme gene B. 
Braun Avitum Hungary CPLC Dialysis Network 
(ACEGENE-BB_HU) study in 1997. Patients of Caucasian 
origin who were on maintenance haemodialysis for more 
than three months and consented for genotyping were 
enrolled in the study. Samples from 716 patients were gen-
otyped. We further excluded 56 patients with severe liver 
disease, active malignancies and haemorrhagic or haemato-
logic diseases from statistical analysis because these disor-
ders may influence the haematological status. The 
remaining primary cohort included 660 patients, who were 
allocated into three subgroups based on their genotype (I/I, 
I/D and D/D). For secondary analysis, we identified match-
ing pairs of patients with I/I and D/D genotype and I/D het-
erozygotes were not included in the secondary analysis. 
Matching variables were gender, age, time on dialysis (the 
following groups were created: less than 12 months, 12–35 
months, 36–59 months, more than 60 months), diabetes and 
the actual use of any ACEi therapy. 127 pairs were identi-
fied. Age was not a strict matching variable because it had 
no significant impact on haemoglobin level. However, we 
strove to match patients with similar age. As a result, 90% 
of the pairs had similar age (±15 years) and in the case of 10 
pairs there were higher range (16–39 years).
Demographic data including age, gender, dialysis vin-
tage, cause of end-stage kidney disease, diabetes status, 
use of ACEi as well as laboratory data and rHuEpo dose 
were extracted from local database.
Ethylenediaminetetraacetic acid (EDTA) samples were 
collected before dialysis and DNA was isolated from 
peripheral blood leukocytes by standard non-enzymatic 
method. Genotyping of the I/D single nucleotide polymor-
phism in intron 16 of the ACE gene was carried out using 
the conventional technique.38 Epoetin alfa was used exclu-
sively as rHuEpo. Erythropoietin resistance index (ERI) 
was calculated from the monthly rHuEpo dose (prescribed 
in the months of blood sampling), divided by the haemo-
globin (g/l) level.
Parameters following normal distribution were reported 
using mean and standard deviation (SD). Parameters with 
non-normal distribution, such as rHuEpo dose, time on 
dialysis and ERI were reported using median and lower–
upper quartiles (Q1–Q3). Differences between two inde-
pendent groups were compared using Student’s t-test and 
Mann-Whitney test. Genotype groups (I/I, I/D and D/D) 
were compared using one-way analysis of variance 
(ANOVA) (Tukey’s test used for post-hoc analysis) or 
Kruskal-Wallis tests for continuous variables and z-test for 
categorical variables. Haemoglobin as a dependent varia-
ble was tested in univariate, multivariate linear regression 
and GLM-analysis (General Linear Model) of covariance 
model. For the comparison of patient’s pairs (I/I versus 
D/D genotype), the dependent samples t-test, the Wilcoxon 
matched pairs test were used, as appropriate. The statisti-
cal analysis was performed by STATISTICA software 
package (version 10, Tulsa, Oklahoma, USA). 
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All patients gave written consent to the genetic testing 
and data collection. The study was approved by the local 
and central ethical committees and it was financially sup-
ported by the Hungarian Scientific Research Fund (OTKA, 
TO23927). This research adhered to the principles of the 
Declaration of Helsinki.
Results
Characteristics of patients are summarised in Table 1. The 
proportions of patients with I/I, I/D and D/D genotypes 
were 20%, 41.5%, and 38.5%, respectively. In the whole 
cohort, male gender was more prevalent (51.7% vs 48.3%), 
mean age was 54.5±16.5 years and patients were on dialy-
sis therapy for two years (23.8 months (11.2–46.6)). ACE 
inhibitor therapy was prescribed for 48.3% and rHuEpo 
therapy for 80.6% of all patients. The most frequent cause 
of end-stage renal disease was coded as glomerulonephritis 
in the patient registry, followed by tubulointerstitial nephri-
tis, diabetes, polycystic kidney disease and hypertension. 
There were no differences in demographic or laboratory 
parameters and rHuEpo doses between the three genotype 
groups. Haemoglobin levels were comparable in the geno-
type groups, and also the proportion of patients receiving 
rHuEpo therapy and rHuEpo doses was similar. The pro-
portion of patients receiving ACEi therapy was also similar 
in the genotype groups. The only significant differences 
were detected in haemoglobin levels (95.5±12.1 g/l vs 
97.4±13.4 g/l, p=0.02) and frequency of rHuEpo therapy 
(86.2% vs 75.4%, p=0.01) between patients with ACEi 
therapy and without ACEi therapy (Table 1). When we fur-
ther analysed this association in different genotype groups, 
we found that haemoglobin levels in patients not receiving 
ACEi therapy were higher in patients with I/D genotype 
(95.2±11 g/l vs 98.2±11.9 g/l, p=0.04) and D/D genotype 
(93.3±13.2 g/l vs 97.4±14.2 g/l, p=0.02), but this difference 
was not found in patients with I/I genotype (97.9±11.6 g/l 
vs 95.9±14.9 g/l, p=0.39). We observed a trend towards 
decreasing haemoglobin levels in I/D and D/D genotype 
groups among patients receiving ACEi therapy (Figure 1).
In univariate linear regression models, higher haemo-
globin levels were associated with male gender, longer 
dialysis vintage and ACEi therapy. In addition to these 
parameters, diabetes emerged as an additional predictor in 
our multivariate model. The ACE gene I/D polymorphism 
(I/I and I/D-D/D) and age were not associated with haemo-
globin levels (Table 2).
In order to further clarify the effects of ACEi therapy on 
haemoglobin levels of patients with different genotypes 
we analysed the combined effect of ACEi therapy and 
ACE I/D polymorphism on haemoglobin in an analysis of 
covariance (ANCOVA) model including dialysis vintage 
as additional covariant factor as well. In this model, nei-
ther ACEi therapy nor ACE gene I/D polymorphism had 
significant impact on the haemoglobin level (p=0.53 for 
T
ab
le
 1
. 
D
em
og
ra
ph
ic
 a
nd
 la
bo
ra
to
ry
 c
ha
ra
ct
er
is
tic
s 
of
 p
at
ie
nt
s 
ba
se
d 
on
 g
en
ot
yp
e 
an
d 
an
gi
ot
en
si
n-
co
nv
er
tin
g 
en
zy
m
e 
in
hi
bi
to
r 
(A
C
Ei
) 
th
er
ap
y.
Pa
ra
m
et
er
s
En
tir
e 
co
ho
rt
M
at
ch
ed
 p
ai
rs
p
A
C
E 
ge
no
ty
pe
p
A
C
Ei
 t
he
ra
py
p
 
II
ID
D
D
A
C
Ei
+
A
C
Ei
–
 
N
um
be
r 
of
 p
at
ie
nt
s 
(%
)
66
0 
(1
00
%
)
25
4 
(1
00
%
)
–
13
2 
(2
0%
)
27
4 
(4
1.
5%
)
25
4 
(3
8.
5%
)
–
31
9 
(4
8.
3%
)
34
1 
(5
1.
7%
)
–
M
al
e,
 %
 (
n)
51
.7
 (
34
1)
54
.3
 (
13
8)
0.
48
53
.8
 (
71
)
51
.8
 (
14
2)
50
.4
 (
12
8)
0.
82
54
.9
 (
17
5)
48
.7
 (
16
6)
0.
11
A
ge
, m
ea
n±
SD
54
.5
±
16
.5
54
,7
±
14
,5
0.
87
54
.8
±
15
,9
54
.1
±
15
,9
54
.7
±
14
,8
0.
88
53
.5
±
15
.0
55
.4
±
15
.9
0.
12
T
im
e 
on
 d
ia
ly
si
s 
(m
on
th
s)
 m
ed
ia
n 
(IQ
R
)
23
.8
 (
11
.2
–4
6.
6)
28
.1
 (
13
.4
–4
7.
9)
0.
23
25
.4
 (
12
.1
–4
9.
2)
23
.8
 (
11
.4
–4
9.
0)
23
.4
 (
10
.7
–4
0.
3)
0.
50
25
.0
 (
11
.1
–4
9.
4)
23
.0
 (
11
.2
–4
2.
1)
0.
11
D
ia
be
te
s,
 %
 (
n)
19
.5
 (
12
9)
17
.3
 (
44
)
0.
45
16
.7
 (
22
)
17
.9
 (
49
)
22
.8
 (
58
)
0.
23
16
. 9
 (
54
)
22
.0
 (
75
)
0.
10
H
ae
m
og
lo
bi
n 
(g
/l)
 
m
ea
n 
±
SD
96
.3
±
12
.8
96
.4
±
13
.0
0.
92
96
.9
±
13
.3
96
.8
±
11
,
95
.4
±
13
.8
0.
37
95
.5
±
12
.1
97
.4
±
13
.4
0.
02
A
C
E 
in
hi
bi
to
r 
th
er
ap
y,
 
%
 (
n)
48
.3
 (
31
9)
51
.2
 (
13
0)
0.
43
50
.7
 (
67
)
46
.7
 (
12
8)
48
.8
 (
12
4)
0.
73
 
rH
uE
po
 t
he
ra
py
, %
 (
n)
80
.6
 (
53
2)
81
.9
 (
20
8)
0.
65
81
.6
 (
10
7)
80
.3
 (
22
0)
80
.7
 (
20
5)
0.
98
86
.2
 (
27
5)
75
.4
 (
25
7)
0.
01
rH
uE
po
 d
os
es
 m
ed
ia
n 
(IQ
R
)
16
00
0 
(1
30
00
–
22
00
0)
18
00
0 
(1
30
00
–
24
00
0)
0.
90
18
00
0 
(1
20
00
–
20
00
0)
16
00
0 
(1
30
00
–
20
00
0)
18
00
0 
(1
30
00
–
24
00
0)
0.
22
16
00
0 
(1
30
00
–
24
00
0)
18
00
0 
(1
20
00
–
20
00
0)
0.
53
ER
I m
ed
ia
n 
(IQ
R
)
18
1.
0 
(1
33
.3
–2
41
.0
)
19
0.
9 
(1
30
.8
–2
42
.4
)
0.
89
18
8.
2 
(1
25
.0
–2
41
.0
)
17
7.
8 
(1
32
.1
–2
25
.0
)
19
8.
3 
(1
39
.7
–2
57
.1
)
0.
13
18
3.
5 
(1
34
.8
–2
42
.4
)
17
9.
9 
(1
28
.7
–2
38
.1
)
0.
53
A
C
E:
 a
ng
io
te
ns
in
-c
on
ve
rt
in
g 
en
zy
m
e;
 D
: d
el
et
io
n;
 E
R
I: 
er
yt
hr
op
oi
et
in
 r
es
is
ta
nc
e 
in
de
x;
 I:
 in
se
rt
io
n;
 IQ
R
: i
nt
er
qu
ar
til
e 
ra
ng
e;
 r
H
uE
po
: r
ec
om
bi
na
nt
 h
um
an
 e
ry
th
ro
po
ie
tin
; S
D
: s
ta
nd
ar
d 
de
vi
at
io
n.
1024 Journal of the Renin-Angiotensin-Aldosterone System 16(4) 
both variables). However, the ANCOVA model and also 
the multivariate regression model revealed significant 
interaction (p=0.02) between ACEi therapy and ACE I/D 
polymorphism.
Since we detected several additional interactions 
between predictor variables, namely gender, dialysis vin-
tage, diabetes, ACE I/D polymorphism and ACEi therapy, 
we decided to use matched-pair analysis in order to con-
trol for those potential confounders. We identified 127 
matched pairs from I/I and D/D genotype groups based on 
gender, age, dialysis vintage, diabetes status, ACEi ther-
apy. Compared to the entire cohort, mean age (54.7±14.5 
vs 54.5±16.5 years), dialysis vintage (28.1 (13.4–47.9) vs 
23.8 (11.2–46.6)), proportion of male subjects (54.3% vs 
51.7%), the prevalence of diabetes (17.3% vs 19.5%) and 
ACE inhibitor use was similar (51.2% vs 48.3%) in the 
paired subcohort. Also, haemoglobin levels (96.4±13.0 g/l 
vs 96.3±12.8 g/l), monthly rHuEpo doses (18,000 
(13,000–24,000) vs 16,000 (13,000–22,000)) and ERI 
values (190.9 (130.8–242.4) vs 181.0 (133.3–241.0)) 
were similar (Table 1).
In the subgroup of 127 pairs, patients were further 
grouped based on ACEi treatment status. In pairs not 
receiving ACEi therapy (62 pairs), monthly rHuEpo doses 
(18,500 (14,500–20,000) IU/month vs 18,000 (12,000–
20,000) IU/month, p=0.73) and haemoglobin levels were 
comparable (95.6±14.1 g/l vs 99.0±12.8 g/l, p=0.14). ERI 
was not different in the two genotype groups (202.0 
(137.2–243.2) vs 177.8 (122.4–225.0), p=0.59). In con-
trast, among patients receiving ACEi therapy (65 pairs), 
D/D genotype was associated with lower haemoglobin 
levels (98.2±11.9 g/l vs 93.0±12.8 g/l, p=0.006) and higher 
ERI (175.0 (116.5–233.0) vs 199.1 (147.9–250.0), p=0.05) 
compared to those with I/I genotype, while rHuEpo doses 
were similar in both groups (16,000 (12,000–24,000) vs 
17,000 (14,000–24,000), p=0.16). (Table 3).
Discussion
In this cross-sectional study among Caucasian patients on 
maintenance haemodialysis, we found that ACEi therapy 
modifies the effect of ACE gene I/D polymorphism on 
erythropoiesis. Our results suggest that in patients with 
D/D genotype or with D allele, the pharmacological inhi-
bition of ACE enzyme can increase erythropoietin resist-
ance and worsen erythropoiesis. We did not find any direct 
association between erythropoietin resistance and ACE 
gene I/D polymorphism alone. To our knowledge, this is 
the first study examining the combined effect of ACE gene 
I/D polymorphism and ACEi therapy on erythropoiesis in 
Caucasian dialysis patients.
These results might provide possible explanations for 
the conflicting findings in earlier studies regarding ACEi 
therapy and erythropoietin resistance in dialysis patients. 
While some studies reported negative effect of ACEis on 
erythropoietin resistance and anaemia in haemodialy-
sis43–46 others could not demonstrate this relationship.35–50 
In our entire cohort, ACEi use was associated with lower 
haemoglobin levels; however, we did not observe this rela-
tionship in the subcohort of patients with II genotype of 
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Figure 1. Effect of angiotensin-converting enzyme inhibitor 
(ACEi) therapy on haemoglobin levels in patients with different 
angiotensin-converting enzyme (ACE) gene insertion/deletion 
(I/D) genotype. Analysis of variance (ANOVA) using Tukey’s 
test for statistical comparisons of groups.
Table 2. Uni- and multivariate linear regression models with haemoglobin as dependent variable.
Univariate model Multivariate model
 ba 95% CI p ba 95% CI p
Gender (female) −2.25 −4.21 to −0.28 0.03 −2.39 −4.36 to −0.42 0.02
Age (10 years increment) −0.05 −0.69 to 0.59 0.87 0.07 −0.60 to 0.73 0.84
Diabetes 1.97 −0.53 to 4.47 0.12 2.71 0.14 to 5.29 0.04
Dialysis vintage (5 years increment) 1.97 0.15 to 3.79 0.03 2.44 0.54 to 4.34 0.01
ACE inhibitor therapy −2.39 −4.35 to −0.42 0.02 −2.53 −4.49 to −0.57 0.01
ACE genotype (I/I and ID+DD) −0.82 −3.29 to 1.65 0.51 −0.83 −3.27 to 1.62 0.51
ACE: angiotensin-converting enzyme; CI: confidence interval; D: deletion; I: insertion;
aRegression coefficient.
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the ACE gene. ACE inhibition was associated with 
increased erythropoietin resistance in patients with D/D or 
I/D genotypes only (Figure 1).
The detected effect of ACE inhibition on haemoglobin 
levels in patients with D/D genotype in our study was also 
clinically relevant. While 42.1% of patients on ACE inhib-
itor therapy reached treatment target of haemoglobin>100 
g/l in the I/I group, only 27% of patients with D/D geno-
type achieved this goal (p=0.05) (data not shown).
Serum and tissue ACE activity and AT-II levels are 
greatly influenced by ACE gene I/D polymorphism: indi-
viduals with the D/D allele have the highest activity of 
ACE.37 In our model, the presumably relative greater fall in 
AT-II levels and endogenous EPO production as a response 
to ACEi therapy in patients with D/D genotype resulted in 
lower haemoglobin levels and higher exogenous rHuEpo 
requirement (also perceived as higher erythropoietin resist-
ance) compared to patients with I/I genotype.
Lower rHuEpo dose requirement was associated with the 
D/D genotype in patients on peritoneal dialysis in the United 
Kingdom in two studies by Varagunam et al. and Sharples et 
al.39,41 These findings are in agreement with our model in 
the sense that D/D genotype is associated with higher AT-II 
levels, an important stimulus of erythropoiesis and also 
higher endogenous erythropoietin levels.43 Therefore, lower 
exogenous rHuEpo doses were required to achieve treat-
ment targets in patients with D/D genotype. However, those 
patient populations might be very unlike our cohort because 
of the different dialysis modality, likely significant residual 
renal function and lower level of chronic inflammation. In 
addition, a greater proportion of our patients received ACEi 
therapy compared to those studies.
Among haemodialysis patients in Korea, Jeong et al.42 
demonstrated lower erythropoietin resistance in patients 
with D/D genotype compared to I/D or I/I genotypes. 
Although we also observed a trend towards higher haemo-
globin levels and lower erythropoietin resistance in our 
matched patients with D/D genotype compared to I/I geno-
type not receiving ACEis, this was statistically not signifi-
cant. Differences in allele frequencies between races and 
the – not documented – distribution of patients with ACEi 
therapy among genotype groups in the referred study could 
be potential explanations for this discrepancy.
There are a number of limitations to this study: (a) 
because of the cross-sectional nature of our study, we 
could not detect temporal changes of haemoglobin levels, 
rHuEpo doses and prescription of ACE inhibitors; (b) in 
addition, we did not capture several potential confounders, 
such as chronic inflammation, iron status and iron therapy, 
parathyroid hormone levels, residual kidney function, dial-
ysis dose, previous kidney transplant and use of immuno-
suppressive medication, smoking habits or alcohol 
consumption that all are likely to affect erythropoiesis in 
haemodialysis patients; (c) furthermore, we did not meas-
ure serum erythropoietin and AT-II levels or ACE activity: 
these might have helped in understanding the pathophysi-
ological background of our results, but are unlikely to 
affect the explored associations; (d) patients were on a 
wide variety of ACEis and we did not capture its type, dos-
age or length of treatment: however, very few studies 
included those data in the analysis, and we are confident 
that including ACEi treatment pattern in the analysis 
would not impact our main findings; (e) many patients fell 
out when using our paired model in the secondary analysis 
Table 3. Comparison of haemoglobin, recombinant human erythropoietin (rHuEpo) dose and erythropoietin resistance index 
(ERI) between genotype pairs in patients with respect to angiotensin-converting enzyme inhibitor (ACEi) therapy.
Parameters ACE genotype p
 II DD  
Entire cohort (127 pairs)
Haemoglobin (g/l) mean±SD 96.9±13.0 96.0±13.1 0.53
On rHuEpo therapy, % (n) 82.7% (105) 81.1% (103) 0.74
rHuEpo median dose (IU/month) (Q1–Q3) 18,000 (12,000–22,000) 18,000 (13,000–24,000) 0,40
ERI median (Q1–Q3) 189.5 (125.0–241.0) 197.5 (133.3–244.9) 0.20
 Not on ACEi therapy (62 pairs)  
Haemoglobin (g/l) mean±SD 95.6±14.1 99.0±12.8 0.14
On rHuEpo therapy, % (n) 77.4 (48) 69.4 (43) 0.40
rHuEpo median dose (IU/month) (Q1–Q3) 18,500 (14,500–20,000) 18,000 (12,000–20,000) 0.73
ERI median (Q1–Q3) 202.0 (137.2–243.2) 177.8 (122.4–225.0) 0.59
 On ACEi therapy (65 pairs)  
Haemoglobin (g/l) mean±SD 98.2±11.9 93.0±12.8 0.006
On rHuEpo therapy, % (n) 87.7 (57) 92.3 (60) 0.55
rHuEpo median dose (IU/month) (Q1–Q3) 16,000 (12,000–24,000) 17,000 (14,000–24,000) 0.16
ERI median (Q1–Q3) 175.0 (116.5–233.0) 199.1 (147.9–250.0) 0.046
ACE: angiotensin-converting enzyme; D: deletion; I: insertion; SD: standard deviation.
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and this might have distorted results; however, we think 
that this sub-cohort was representative for the entire study 
population; (f) more importantly, since we included only 
patients of Caucasian origin into our database, our results 
might not be generalisable to patients of other races.
Despite those limitations, our results might have clini-
cal implications concerning the management of renal 
anaemia. About 5–10% of patients on haemodialysis 
receiving rHuEpo have high erythropoietin resistance. If 
ACEi treatment can be a contributing factor to the resist-
ance, a trial of holding ACEi therapy could potentially 
result in increased erythropoiein response in some patients, 
likely those with D allele in their ACE gene.
Conclusions
We confirmed that the variable effect of ACE inhibition on 
erythropoiesis is linked to the polymorphism of the ACE 
gene. ACEi therapy in patients with the D/D genotype or D 
allele resulted in lower haemoglobin levels and higher 
erythropoietin resistance compared to patients with the I/I 
genotype. Our study might provide an additional argument 
for individualised therapies in the future, when detecting 
genetic polymorphisms might be part of personalised man-
agement of end-stage renal disease patients.
Acknowledgement
The authors thank András Paksy for his invaluable help in the 
statistical analysis.
ACEGENE-BB_HU Workgroup’s collaborators from B. Braun 
Avitum Hungary CPLC Dialysis Network: Attila Benke 
(Veszprém), Béla Borbás (Debrecen), Sándor Ferenczi (Győr), 
Mária Hengsperger (Mátészalka), Szilvia Kazup (Siófok), Lajos 
Nagy (Tatabánya), József Németh (Dunaújváros), Antal Rozinka 
(Kisvárda), Tamás Szabó (Kistarcsa), Tamás Szelestei (Kaposvár), 
Eszter Tóth (Békéscsaba, Gyula), Gábor Varga (Ajka), Gyula 
Wágner (Szekszárd), Gábor Zakar (Székesfehérvár).
Conflict of interest
None declared.
Funding
The authors wish to thank Csaba Szalay for the determination of 
the ACE gene polymorphism, which was funded by the Hungarian 
Scientific Research Fund (OTKA, TO23927/1997). This work 
was also supported by B.Braun Avitum Hungary CPLC Dialysis 
Network.
References
 1. Astor BC, Muntner P, Levin A, et al. Association of kid-
ney function with anemia: The Third National Health and 
Nutrition Examination Survey (1988–1994). Arch Intern 
Med 2002; 162: 1401–1408.
 2. Macdougall IC. Poor response to erythropoietin: Practical 
guidelines on investigation and management. Nephrol Dial 
Transplant 1995; 10: 607–614.
 3. Bamgbola OF. Pattern of resistance to erythropoietin-
stimulating agents in chronic kidney disease. Kidney Int 
2011; 80: 464–474.
 4. Molnar MZ, Czira M, Ambrus CS, et al. Anemia is asso-
ciated with mortality in kidney-transplanted patients–a 
prospective cohort study. Am J Transplant 2007; 7: 818–
824. 
 5. Szczech LA, Barnhart HX, Inrig JK, et al. Secondary analy-
sis of the CHOIR trial epoetin-alpha dose and achieved 
hemoglobin outcomes. Kidney Int 2008; 74: 791–798.
 6. Kaysen GA, Müller HG, Ding J, et al. Challenging the 
validity of the EPO index. Am J Kidney Dis 2006; 47: 
157–166.
 7. Zhang Y, Thamer M, Stefanik K, et al. Epoetin requirements 
predict mortality in hemodialysis patients. Am J Kidney Dis 
2004; 44: 866–876.
 8. Macdougall IC. The role of ACE inhibitors and angiotensin 
II receptor blockers in the response to epoetin. Nephrol Dial 
Transplant 1999; 14: 1836–1841.
 9. Mrug M, Juliana BA and Prchal JT. Angiotensin-II recep-
tor type 1 expression in erythroid progenitors: Implications 
for the pathogenesis of postrenal transplant erythrocytosis. 
Semin Nephrol 2004; 24: 120–130.
 10. Vlahakos DV, Marathias KP and Madias NE. The role of 
the renin-angiotensin system in the regulation of erythro-
poiesis. Am J Kidney Dis 2010; 56: 558–565.
 11. Nakao K, Shirakura T, Azuma M, et al. Studies on erythro-
poietic action of angiotensin II. Blood 1967; 29: 754–760.
 12. Azizi M, Rousseau A, Ezan E, et al. Acute angiotensin-
converting enzyme inhibition increases the plasma level 
of the natural stem cell regulator n-acethyl-seryl-aspartyl-
lysyl-proline. J Clin Invest 1996; 97: 839–844.
 13. Le Meur Y, Lorgeot V, Comte L, et al. Plasma levels and 
metabolism of AcSDKP in patients with chronic renal fail-
ure: Relationship with erythropoietin requirements. Am J 
Kidney Dis 2001; 38: 510–517.
 14. Mrug M, Stopka T, Julian BA, et al. Angiotensin II stimu-
lates proliferation of normal early erythroid progenitors. J 
Clin Invest 1997; 100: 2310–2314.
 15. Rodgers KE, Xiong S, Steer R, et al. Effect of angiotensin 
II on hematopoietic progenitor cell proliferation. Stem Cells 
2000; 18: 287–294.
 16. Fisher JW, Samuels AI and Langston JW. Effects of angio-
tensin and renal artery constriction on erythropoietin pro-
duction. J Pharmacol Exp Ther 1967; 157: 618–625.
 17. Freudenthaler SM, Schreeb KH, Körner T, et al. Angiotensin 
II increases erythropoietin production in healthy human vol-
unteers. Eur J Clin Invest 1999; 29: 816–823.
 18. Gossmann J, Burkhardt R, Harder S, et al. Angiotensin II 
infusion increases plasma erythropoietin levels via an angi-
otensin II type 1 receptor-dependent pathway. Kidney Int 
2001; 60: 83–86
 19. Pratt MC, Lewis-Barned NJ, Walker RJ, et al. Effect of 
angiotensin converting enzyme inhibitors on erythropoietin 
concentrations in healthy volunteers. Br J Clin Pharmac 
1992; 34: 363–365.
 20. Gupta M, Miller BA, Ahsan N, et al. Expression of angio-
tensin II type 1 receptor on erythroid progenitors of patients 
with post transplant erythrocytosis. Transplantation 2000; 
70: 1188–1194.
Kiss et al. 1027
 21. Glicklich D, Burris L, Urban A, et al. Angiotensin-
converting enzyme inhibition induces apoptosis in erythroid 
precursors and affects insulin-like growth factor-1 in post-
transplantation erythrocytosis. J Am Soc Nephrol 2001; 12: 
1958–1964.
 22. Usalan C, Erdem Y, Caglar M, et al. Effect of enalapril on 
exaggerated erythropoietin response to phlebotomy in eryth-
rocytosic renal transplant patients. Nephrol Dial Transplant 
1998; 13: 2884–2889.
 23. Julian BA, Brantley JR Brantley JR. RR, Barker CV, et al. 
Losartan, an angiotensin II type 1 receptor antagonist, low-
ers hematocrit in posttransplant erythrocytosis. J Am Soc 
Nephrol 1998; 9: 1104–1108.
 24. Marrero MB, Schieffer B, Paxton WB, et al. Direct stimula-
tion of Jak/STAT pathway by the angiotensin II AT1 recep-
tor. Nature 1995; 375: 247–250.
 25. Elliott S, Pham E and Macdougall IC. Erythropoietins: 
A common mechanism of action. Exp Hematol 2008; 36: 
1573–1584.
 26. Morrone LF, Di Paolo S, Logoluso F, et al. Interference of 
angiotensin-converting enzyme inhibitors on erythropoiesis 
in kidney transplant recipients: Role of growth factors and 
cytokines. Transplantation 1997; 64: 913–918.
 27. Constantinescu CS, Goodman DB and Ventura ES. Captopril 
and lisinopril suppress production of interleukin-12 by 
human peripheral blood mononuclear cells. Immunol Lett 
1998; 62: 25–31.
 28. Hirakata H, Onoyama K, Iseki K, et al. Worsening of ane-
mia induced by long-term use of captopril in hemodialysis 
patients. Am J Nephrol 1984; 4: 355–360.
 29. Ertürk S, Ates K, Duman N, et al. Unresponsiveness to 
recombinant human erythropoietin in haemodialysis patients: 
Possible implications of angiotensin-converting enzyme 
inhibitors. Nephrol Dial Transplant 1996; 11: 396–397.
 30. Albitar S, Genin R, Fen-Chong M, et al. High dose enal-
april impairs the response to erythropoietin treatment in 
haemodialysis patients. Nephrol Dial Transplant 1998; 13: 
1206–1210, 1998
 31. Ertürk S, Nergizoglu G, Ates K, et al. The impact of with-
drawing ACE inhibitors on erythropoietin responsiveness 
and left ventricular hypertrophy in haemodialysis patients. 
Nephrol Dial Transplant 1999; 14: 1912–1916.
 32. Mora C and Navarro JF. Negative effect of angiotensin-
converting enzyme inhibitors on erythropoietin response in 
CAPD patients. Am J Nephrol 2000; 20: 248.
 33. Odabas AR, Cetinkaya R, Selcuk Y, et al. The effect of high 
dose losartan on erythropoietin resistance in patients under-
going haemodialysis. Panminerva Med 2003; 45: 59–62.
 34. Nakamoto H, Kanno Y, Okada H, et al. Erythropoietin 
resistance in patients on continuous ambulatory peritoneal 
dialysis. Adv Perit Dial 2004; 20: 111–116.
 35. Cruz DN, Perazella MA, Abu-Alfa AK, et al. Angiotensin-
converting enzyme inhibitor therapy in chronic hemodialy-
sis patients: Any evidence of erythropoietin resistance? Am 
J Kidney Disises 1996; 28: 535–540.
 36. Charytan C, Goldfarb-Rumyantzev A, Wang YF, et al. 
Effect of angiotensin-converting enzyme inhibitors on 
response to erythropoietin therapy in chronic dialysis 
patients. Am J Nephrol 1998; 18: 498–503.
 37. Rigat B, Hubert C, Alhenc-Gelas F, et al. An insertion/dele-
tion polymorphism in the angiotensin I-converting enzyme 
gene accounting for half the variance of serum enzyme lev-
els. J Clin Invest 1990; 86: 1343–1346.
 38. Rigat B, Hubert C, Corvol P, et al. PCR detection of the 
insertion/deletion polymorphism of the human angiotensin 
converting enzyme gene (DCP1) (dipeptidyl carboxypepti-
dase 1). Nucleic Acids Res 1992; 20: 1433.
 39. Varagunam M, McCloskey DJ, Sinnott PJ, et al. Angiotensin-
converting enzyme gene polymorphism and erythropoietin 
requirement. Perit Dial Int 2003; 23: 111–115.
 40. Jimeno L, Rodado R, Barrios Y, et al. Influence of angio-
tensin-converting enzyme polymorphism gene, IGF-1, and 
other factors in the response rate of hematocrit to enalapril 
treatment in patients with posttransplant erythrocytosis. 
Transplantation Proc 2005; 37: 1012–1013.
 41. Sharples EJ, Varagunam M, Sinnott PJ, et al. The effect of 
proinflammatory cytokine gene and angiotensin-converting 
enzyme polymorphisms on erythropoietin requirements in 
patients on continuous ambulatory peritoneal dialysis. Perit 
Dial Int 2006; 26: 64–68.
 42. Jeong KH, Lee TW, Ihm CG, et al. Polymorphisms in two 
genes, IL-1B and ACE, are associated with erythropoietin 
resistance in Korean patients on maintenance hemodialysis. 
Exp Mol Med 2008; 40: 161–166.
 43. Hatano M, Yoshida T, Mimuro T, et al. The effects of ACE 
inhibitor treatment and ACE gene polymorphism on eryth-
ropoiesis in chronic hemodialysis patients. Nihon Jinzo 
Gakkai Shi 2000; 42: 632–639.
 44. Hess E, Spershneider H and Stein G. Do ACE inhibitors 
influence the dose of human recombinant erythropoietin in 
dialysis patients? Nephrol Dial Transplant 1996; 11: 749–
751.
 45. Schiffl H and Lang SM. Angiotensin-converting enzyme 
inhibitors but not angiotensin II AT 1 receptor antagonists 
affect erythropoiesis in patients with anemia of end-stage 
renal disease. Nephron 1999; 81: 106–108
 46. Matsumura M, Nomura H, Koni I, et al. Angiotensin-
converting enzyme inhibitors are associated with the need 
for increased recombinant human erythropoietin mainte-
nance doses in hemodialysis patients. Risk of cardiac dis-
ease in dialysis patients study group. Nephron 1997; 77: 
164–168.
 47. Sanchez JA. ACE inhibitors do not decrease rHuEPO 
response in patients with end-stage renal failure. Nephrol 
Dial Transplant 1995; 10: 1476–1477.
 48. Abu-Alfa AK, Cruz D, Perazella MA, et al. ACE inhibitors 
do not induce recombinant human erythropoietin resistance in 
hemodialysis patients. Am J Kidney Dis 2000; 35: 1076–1082.
 49. Saudan P, Halabi G, Perneger T, et al. ACE inhibitors or 
angiotensin II receptor blockers in dialysed patients and 
erythropoietin resistance. J Nephrol 2006; 19: 91–96.
 50. Hayashi K, Hasegawa K and Kobayashi S. Effects of angio-
tensin-converting enzyme inhibitors on the treatment of ane-
mia with erythropoietin. Kidney Int 2001; 60: 1910–1916.
